Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-11-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Online Access: | http://www.dovepress.com/corrigendum-agomelatine-as-monotherapy-for-major-depression-an-ou-a15090 |
| Summary: | Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current study was much higher than in the 6-week and 8-week double-blind, placebo-controlled studies of agomelatine13,36 and higher than in an observational study of different antidepressants where a 38.2% early remission rate and a 20.5% early response rate were found at week 6 of treatment,41 but similar to a double-blind study comparing agomelatine with fluoxetine in patients with severe depression."42Read the original article |
|---|---|
| ISSN: | 1176-6328 1178-2021 |